Core Viewpoint - Corcept Therapeutics Inc. is under investigation by Block & Leviton for potential securities law violations following a significant drop in its stock price after receiving a Complete Response Letter from the FDA regarding its drug relacorilant [1][2]. Group 1: Company Overview - Corcept Therapeutics' shares fell more than 50% on December 31, 2025, due to the FDA's Complete Response Letter indicating the need for additional evidence of effectiveness for relacorilant [2]. - The company is facing scrutiny as investors who have lost money in their investments are encouraged to contact Block & Leviton for potential recovery options [1][3]. Group 2: Legal Investigation - Block & Leviton is investigating whether Corcept Therapeutics committed securities law violations and may file an action to recover losses for affected investors [4]. - Investors who purchased Corcept Therapeutics common stock and experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they sold their shares [3]. Group 3: Whistleblower Information - Individuals with non-public information about Corcept Therapeutics are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Group 4: Firm's Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - Scott+Scott Attorneys at Law LLP is investigating Corcept Therapeutics Incorporated for potentially issuing misleading statements and failing to disclose material information to investors, which may violate federal securities laws [1]. Company Overview - Corcept Therapeutics is a pharmaceutical company focused on discovering, developing, and commercializing drugs for severe metabolic, psychiatric, and oncologic disorders [2]. Recent Developments - On December 31, 2025, Corcept announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant, indicating that the FDA could not determine a favorable benefit-risk assessment without additional evidence of effectiveness from Corcept [3]. - Following the FDA's announcement, Corcept's stock price dropped over 50%, closing at $34.80 per share on December 31, 2025 [3].

Group 1 - Block & Leviton is investigating Corcept Therapeutics Inc. for potential securities law violations following a significant drop in share price [1][2] - Corcept Therapeutics' shares fell over 50% on December 31, 2025, after the company received a Complete Response Letter from the FDA regarding relacorilant, indicating the need for additional evidence of effectiveness [2] - Investors who purchased Corcept Therapeutics common stock and experienced a loss may be eligible to participate in the investigation [3] Group 2 - Block & Leviton is assessing whether Corcept Therapeutics committed securities law violations and may file an action to recover losses for affected investors [4] - The firm encourages investors who have lost money to contact them for further information and assistance [5] - Whistleblowers with non-public information about Corcept Therapeutics are invited to assist in the investigation, with potential rewards for information leading to successful recovery [6] Group 3 - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7]

Core Insights - Corcept Therapeutics is a mid-cap biotechnology company focused on therapies for severe endocrine and oncologic conditions, leveraging cortisol modulation to meet unmet medical needs with a growing portfolio of proprietary drug candidates [1] - The company generates revenue primarily from Korlym, an FDA-approved therapy for Cushing's syndrome, and is advancing a pipeline of selective cortisol modulators targeting various disorders [2] Transaction Details - William Guyer, the chief development officer, exercised 20,000 stock options and sold the resulting shares for approximately $703,656, which reflects a significant transaction involving direct common stock holdings [4] - Following this transaction, Guyer's direct common stock holdings decreased from 21,235 shares to 1,235 shares, a reduction of 94.18%, although he retains stock options for 250,000 shares [3] Financial Performance - Corcept reported third-quarter revenue of $207.6 million, an increase from $182.5 million year-over-year, driven by growth in Korlym prescriptions [6] - The company reaffirmed its full-year revenue guidance of $800 million to $850 million and ended the quarter with $524 million in cash and investments, indicating strong balance sheet flexibility [6] Market Context - The stock experienced a sharp decline on December 31 following an FDA complete response letter for relacorilant; however, the transaction by Guyer is viewed as a portfolio management decision rather than a shift in long-term outlook [5][7] - The core business remains strong despite regulatory setbacks, with the focus on clinical execution and the future of relacorilant being more critical than the recent stock transaction [7]

Core Viewpoint - Scott+Scott Attorneys at Law LLP is investigating Corcept Therapeutics for potentially issuing misleading statements and failing to disclose material information to investors, which may violate federal securities laws [1]. Company Overview - Corcept Therapeutics is a pharmaceutical company focused on discovering, developing, and commercializing drugs for severe metabolic, psychiatric, and oncologic disorders [2]. Recent Developments - On December 31, 2025, Corcept announced that the U.S. FDA issued a Complete Response Letter regarding the New Drug Application for relacorilant, indicating that additional evidence of effectiveness is required for a favorable benefit-risk assessment [3]. - Following the FDA's announcement, Corcept's stock price dropped over 50%, closing at $34.80 per share on the same day [3].

Core Insights - Corcept Therapeutics Incorporated (NASDAQ:CORT) is identified as one of the 12 stocks expected to rebound according to Wall Street analysts [1] - Canaccord Genuity has reduced its price target for Corcept from $140 to $99 while maintaining a Buy rating, following the FDA's Complete Response Letter regarding the New Drug Application for relacorilant [1] - H.C. Wainwright has also lowered its price target from $145 to $90, anticipating a three-year delay in the launch of relacorilant for Cushing's syndrome, now expected in Q1 2029 [3] Business Performance - Despite the FDA's decision, Corcept's Korlym business is performing well, with Canaccord Genuity viewing the recent share sell-off as a buying opportunity due to continued growth prospects for Korlym and its authorized generic version [2] - The Complete Response Letter does not impact the ongoing FDA review of relacorilant for platinum-resistant ovarian cancer, which has a PDUFA date set for July 11, 2026 [4] Company Focus - Corcept Therapeutics is a commercial-stage pharmaceutical company dedicated to developing treatments for serious disorders through cortisol modulation [4]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Corcept Therapeutics Incorporated for possible violations of federal securities laws and unlawful business practices following a significant stock price drop after an FDA response regarding a new drug application [1][2]. Investigation Details - On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter regarding its New Drug Application for relacorilant, which is intended for treating hypertension secondary to hypercortisolism. The FDA acknowledged that Corcept's pivotal GRACE trial met its primary endpoint but required additional evidence of effectiveness before making a favorable benefit-risk assessment. Following this announcement, Corcept's stock price fell by $35.40 per share, a decrease of 50.42%, closing at $34.80 per share [2]. Next Steps - Investors who purchased or acquired Corcept shares and experienced losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims. The firm offers consultations without any cost or obligation [3]. About Bragar Eagel & Squire, P.C. - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in various types of litigation, including securities and commercial cases. The firm operates nationwide and handles cases in both federal and state courts [4].

Group 1 - Corcept Therapeutics Incorporated is currently under investigation for potential fraud, providing an opportunity for investors to join the investigation with the Schall Law Firm [1]

Core Viewpoint - Corcept Therapeutics experienced a significant decline in share price, dropping 50% after receiving a complete response letter from the FDA regarding its treatment relacorilant for hypercortisolism, leading to a loss of over $3.6 billion in market capitalization [1][3]. Company Overview - Corcept Therapeutics has previously promoted relacorilant's efficacy and commercial potential, claiming that clinical trial patients showed meaningful improvements in hypercortisolism symptoms [3]. - The company expressed confidence in achieving annual revenues of $3 billion to $5 billion from its hypercortisolism business within three to five years [3]. FDA Response - The FDA's complete response letter indicated that additional evidence of relacorilant's effectiveness was required for a favorable benefit-risk assessment [3]. - A reported finding indicated that loss of blood pressure control was 83% less likely in the relacorilant group compared to placebo [3]. Market Reaction - Following the FDA's announcement, Corcept's share price fell over $35, resulting in a 50% decrease in value on December 31, 2025 [1][3].

Core Insights - Scott+Scott Attorneys at Law LLP is investigating Corcept Therapeutics Incorporated for potentially issuing misleading statements and failing to disclose material information to investors, which may violate federal securities laws [1][3]. Company Overview - Corcept Therapeutics is a pharmaceutical company focused on the discovery, development, and commercialization of drugs for severe metabolic, psychiatric, and oncologic disorders [2]. Recent Developments - On December 31, 2025, Corcept announced that the U.S. Food and Drug Administration issued a Complete Response Letter regarding the New Drug Application for relacorilant, indicating that additional evidence of effectiveness is required for a favorable benefit-risk assessment [3]. - Following the FDA's announcement, Corcept's stock price dropped over 50%, closing at $34.80 per share on the same day [3].